At EicOsis we are responding to the pressing need for safe, effective and non-addictive treatments for those struggling with pain. EicOsis has received funding through competitive grants from federal agencies and angel investors and has recently advanced its lead drug candidate for pain to first-in-human clinical trials. Learn more about what is going on at EicOsis through our most recent press releases. Don’t forget to sign up to receive all our news and updates!
EicOsis drug candidate for pain, EC5026, is currently undergoing clinical trials
July 2024: EicOsis Successfully Completes Phase 1b Clinical Trial of EC5026 in Healthy Humans
EicOsis announces the successful completion of a Phase 1b multiple-ascending dose clinical trial of EC5026, their oral drug candidate for the treatment of pain and inflammation. The double-blind, placebo-controlled Phase 1b study was designed to investigate the safety and pharmacokinetics of daily doses of EC5026 or placebo over seven consecutive days. The evaluated escalating dose regimens of EC5026 were found to be safe and well tolerated by male and female healthy subjects. The pharmacokinetic profile indicates that EC5026 is suitable for once daily oral dosing. EicOsis plans to initiate their first patient study later this year to evaluate safety and pain reduction in patients with neuropathic pain due to spinal cord injury.
January 2024: EicOsis Initiates Phase 1b Clinical Trial of EC5026
EicOsis has initiated Phase 1b multiple-ascending dose clinical trial to test the safety of its oral drug candidate for the treatment of pain, EC5026. The double-blind, placebo-controlled Phase 1b study is designed to investigate the safety and pharmacokinetics of daily doses of EC5026 or placebo over seven days. Initial results show no apparent changes in vital signs, behavior effects, or clinically significant adverse effects in any subjects. Read more.
November 2020: EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026
EicOsis Human Health announced the successful completion of a Phase 1a single-ascending dose clinical trial of EC5026, their oral drug candidate for the treatment of pain. No drug-related adverse events or changes in vital signs or clinical labs were observed, and the final clinical study report concludes that EC5026 is safe and well tolerated when given as a single oral dose ranging from 0.5 to 24 mg. The pharmacokinetic profile indicates that EC5026 is suitable for once daily oral dosing. Read more.
April 2020: EicOsis EC5026 has been Granted Fast Track Designation by the FDA for the treatment of neuropathic pain
EicOsis LLC announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application. Read more.
December 2019: EicOsis Announces First Subject Dosed in the First Phase 1a Clinical Trial of EC5026
EicOsis LLC today announced initiation of dosing for the first human subject in a Phase 1 trial of EC5026, the company’s lead product candidate for pain management. This Phase 1a, single-ascending dose trial will evaluate the safety and tolerability of single oral doses of EC5026 in healthy volunteers. Read more
October 2019: EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain
EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble epoxide hydrolase (sEH) enzyme, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1 clinical trials for their drug candidate, EC5026 (BPN-19186), for the treatment of pain. EicOsis anticipates starting Phase 1 clinical trials in healthy volunteers before the end of this year. Read more
August 2019: The structure of the sEHI for human pain trials was presented at the First Time Disclosure Symposium at the Fall American Chemical Society Meeting.
EicOsis revealed the chemical structure of EC5026 – the first soluble epoxide hydrolase (sEH) inhibitor targeting pain to make it into human clinical trials. The molecule was disclosed at the American Chemistry Society national meeting on August, 2019. Read more
EicOsis in Bloomberg – Business Week on Opioid Replacements for Pain Treatment
EicOsis is developing a completely new therapeutic approach for the treatment of pain. EicOsis new drug is aiming at replacing and reducing the use of opioids. Read more
EicOsis has been awarded over 20 million in competitive grants
October 2019: EicOsis Announces SBIR Grant Award from NCI/NIH
The National Institute of Health has awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute to EicOsis, LLC to support preclinical testing of soluble epoxide inhibitors for treating neuropathic pain associated with chemotherapy drugs. Read more
October 2019: EicOsis Receives $15 million from NIDA to Help Fund Trials of Non-opioid Pain Therapy
The National Institute on Drug Abuse has awarded a grant to EicOsis, LLC as part of the NIH Initiate Helping to End Addition Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in preclinical animal studies. Read more
March 2019: EicOsis Raises funding for Phase 1 Clinical Development Program of Novel Pain Therapeutic
EicOsis Human Health recently received a $5 million investment from Open Philanthropy to support clinical trials on a novel, non-opioid, oral therapy for neuropathic and inflammatory pain. Read more
January 2016: EicOsis Receives $4 Million to Develop Novel Treatment for Diabetic Neuropathic Pain
EicOsis, LLC was awarded a federal grant totaling over $4 million to advance compounds through Phase 1 clinical trials for diabetic neuropathic pain. The grant, “Development of an Oral Analgesic for Neuropathic Pain”, is funded through The National Institutes of Health (NIH) Blueprint for Neuroscience Research. Read more
EicOsis is an innovation leader in the local community
October 2024: EicOsis Among 2024 Most Fundable Companies
EicOsis has been selected as one of the 2024 Pepperdine Graziadio Business School Most Fundable Companies. In their 7th year, Pepperdine Graziadio Business School evaluated more than 2,000 early-stage US startups from across all 50 states. EicOsis was selected as one of the 18 Most Fundable Companies, considered by the Business School as worthy of serious investor consideration based on several company variables including financial projections, market opportunity, intellectual property, competitive advantage, and management-team expertise. As a winner on the Most Fundable Companies List, EicOsis will be profiled on Entrepreneur.com and will be featured in the December print issue of Entrepreneur magazine. EicOsis recently completed three Phase 1 clinical trials of its lead compound, EC5026, in healthy volunteers. EicOsis plans to initiate their first patient study later this year to evaluate safety and pain reduction in patients with neuropathic pain due to spinal cord injury.
November 2019: EicOsis Named Sacramento’s Most Innovative BioPharma Company
EicOsis was awarded the 2019 Sacramento Region Innovation Award in Medical & Health – Biopharma for developing a first-in-class, non-opioid therapy for treatment of inflammatory and neuropathic pain in humans and companion animals. Read more
